Dalcetrapib (JTT-705) is a cholesteryl ester transfer protein (CETP) inhibitor for rhCETP with an IC50 of 0.2 μM. Dalcetrapib modulates CETP activity. Dalcetrapib induces a conformational change in CETP, when added to human plasma. CETP-induced pre-β-HDL formation in human plasma is unchanged by Dalcetrapib ≤3 µM and increased at 10 µM. Dalcetrapib statistically and significantly increases pre-β-HDL formation.Dalcetrapib achieves 50% inhibition of CETP activity in human plasma at a concentration of 9 μM. Dalcetrapib inhibits the CETP activity of media in HepG2 in a dose-dependent manner. Treatment with Dalcetrapib results in significant increases in HDL-C levels. In hamsters injected with [3H]cholesterol-labeled autologous macrophages Dalcetrapib significantly increases fecal elimination of both [3H]neutral sterols and [3H]bile acids. Dalcetrapib increases plasma HDL-[3H]cholesterol.Dalcetrapib has 95% inhibition of CETP activity in male Japanese white rabbits at an oral dose of 30 mg/kg. Dalcetrapib increases the plasma HDL cholesterol level by 27% and 54%, respectively, when given at oral doses of 30 mg/kg or 100 mg/kg once a day for 3 days to male Japanese white rabbits.Treatment with Dalcetrapib markedly increases serum levels of HDL-C. The ratio of HDL2-C to HDL3-C is significantly higher in Dalcetrapib–treated rabbits than in control rabbits at 5 and 7 months, indicating that the inhibition of CETP activity by Dalcetrapib changes the distribution of HDL subfractions and preferentially increases HDL2-C levels. Dalcetrapib treatment increases serum paraoxonase activity and HDL-associated platelet-activating factor acetylhydrolase activity, but decreases the plasma lysophosphatidylcholine concentration. High-density lipoprotein cholesterol increases associated with co-administration of Dalcetrapib with ezetimibe (+29.8%) are comparable with those with Dalcetrapib alone (+25.6%), while the reduction in low-density lipoprotein cholesterol with co-administration (−35.9%) is greater than with ezetimibe alone (−20.9%). Dalcetrapib is generally well tolerated when administered alone and when co-administered with ezetimibe. The HDL-C increase with Dalcetrapib was not compromised by coadministration with statins, and reduction in low-density lipoprotein cholesterol with Dalcetrapib coadministered with statins was greater than with statins alone. Dalcetrapib alone and coadministered with statins was generally well tolerated. Dalcetrapib has enered in a phase III clinical trial in the treatment of cardiovascular disease, dyslipidemia, peripheral arterial disease (PAD).
Cell Experiment | |
---|---|
Cell lines | HepG2 cells |
Preparation method | Seeding the HepG2 cells in 6-well plates and cultured to 70–80% confluence. After being washed with PBS, incubating the cells with growth medium and a different concentration (0 μM–30 μM) of chemical inhibitor Dalcetrapib and dissolving in 2% DMSO for 24 hours. Total RNA is used for RT-PCR. |
Concentrations | 0-30 μM |
Incubation time | 24 hours |
Animal Experiment | |
---|---|
Animal models | Syrian hamsters |
Formulation | 0.5% methylcellulose |
Dosages | 100 mg/kg |
Administration | Oral gavage |
Molecular Weight | 389.59 |
Formula | C23H35NO2S |
CAS Number | 211513-37-0 |
Solubility (25°C) | DMSO 70 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[1] Eric J Niesor, et al. Inhibition of the 3CL Protease and SARS-CoV-2 Replication by Dalcetrapib
[3] Donald M Black, et al. Clinical Pharmacokinetics and Pharmacodynamics of Dalcetrapib
[5] Jennifer G Robinson. Dalcetrapib: a review of Phase II data
Related CETP Products |
---|
Obicetrapib
Obicetrapib is a selective, orally active cholesterol transporter protein (CETP) inhibitor that blocks the function of CETP and significantly reduces LDL-C while significantly increasing HDL-C levels, and may be used in studies related to atherosclerosis and Alzheimer's disease (AD). |
Evacetrapib
Evacetrapib (LY2484595) is a potent and selective inhibitor of CETP which inhibited human recombinant CETP protein (5.5 nM IC(50)) and CETP activity in human plasma (36 nM IC(50)) in vitro. |
Anacetrapib
Anacetrapib is an orally active and potent inhibitor of CETP with IC50 of 7.9 nM and 11.8 nM for rhCETP and mutant CETP(C13S) respectively. |
Torcetrapib
Torcetrapib (CP-529414) is a prototype cholesteryl ester transfer protein (CETP) inhibitor with potential for decreasing atherosclerotic disease, increased cardiovascular events in clinical trials. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.